QNTA is very much undervalued.
The true value of it is astronomical.
It is too early in the process to determine how long and how high the value will go.
April 13, 2020
Quanta, Inc. announced today that it has filed its final set of data requested by the US Food and Drug Administration (FDA) for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19 therapeutic. Along with the submission of a batch of Escozine® previously announced specifically produced for the FDA, the Company believes that this will be the last submission necessary in order to receive IND designation from the regulatory body in the United States.
The Company assembled detailed information regarding the manufacturing of Escozine®, clarity on dosing, as well as both previous and new safety and efficacy data derived from an on-going human study taking place in the DR. The study has been conducted on over 500 participants and intends to demonstrate the safety and efficacy of Escozine®. Escozine® is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife, which has been filed with the FDA under the IND regulatory pathway as well as the Ministry of Health in the DR where the Company is seeking product registration. Previous clinical data was submitted to the FDA including preliminary results of the safety study, which has now been expanded upon. This data, as well as the batch of Escozine® that was produced specifically for the FDA, has now been submitted. After the review of the data and barring any further inquiries or requests, the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US. After such designation, the Company will pursue other clinical applications of Escozine®, including as a potential cancer therapeutic where the Company has already released positive clinical results.
“The FDA-approved therapeutic drug market is the gold standard globally and should we receive IND designation from the FDA, it would catapult our other research across the world,” said Medolife CEO Dr. Arthur Mikaelian. “Submission to the FDA is never easy, but we are generating such positive clinical trial results that we are confident the regulatory body will take notice. They have been reviewing our submission for some time, requesting various other information that we have now submitted. I believe this could be the last request ahead of approval, which would be tremendous not only for our Company, but for patients who are in need of a solution where one does not currently exist. An approval from the FDA would also propel interest from the scientific community on the potential therapeutic benefits of the natural peptides we are studying, including investment and partnership interest.”
IND for Covid-19 therapeutic use first and then others to follow.
Scorpion Venom has the potential to be used in many areas for solutions to different diseases.
ESCOZINE GNP-1™ is in research and development as an advanced anti-cancer drug. Polarized gold nanoparticles combined with a novel peptide extracted from the Caribbean Blue Scorpion venom, potentiates the bioactive compound and increases the effectiveness of the natural compound up to synthetic drug strength by efficiency. The result is a new category of powerful medications without considerable side effects.
Patch – preparing to apply for FDA approval
Four types of Escozine patch are in the research and development stage and these will provide an easy, targeted and effective delivery solution for the product. The enhanced transdermal technology system will allow Escozine’s small molecule peptide to pass through skin’s barrier layer of stratum corneum directly to the target location. The patches that are being developed are:
Breast Patch
Prostate Patch
Skin Patch
Immune Enhancer Patch
Injectable – preparing to apply for FDA approval
Medolife expects to have promising results with an injectable version which is currently in research and development. The product will be directly injected into the tumor by normal injectable methods or by Electrophoresis.
In many cases, doctors cannot perform necessary surgery or use chemotherapy because of tumor location or the patient’s health condition.
Escozine Injectable can become a useful tool for doctors and surgeons.
I.V (Intravenous) – preparing to apply for FDA approval
For those who require a more monitored treatment process, the intravenous version will provide an effective solution for doctors. This version of the product is in research and development in cooperation with Synthesis Laboratories.
Patent
The basic principle described in the US Patent # US 8097284 B2 leads to molecular excitement of vibration produced by an electromagnetic field generator, leading to absorption of the quanta of energy for higher potency of the blue scorpion extract, which increases its effectiveness on overall human health at a deep cellular level. Specific frequencies, as well as harmonics, are used to achieve a resonance effect between the generated electromagnetic frequencies and the molecular frequency of the small molecular peptide, specific amino-acids and 59 essential minerals contained in the blue scorpion extract; the electromagnetic vibrational frequency acts as an energy donor and components contained in the scorpion extract act as an energy acceptor. This energy transfer gives more strength, force and potency to the Blue Scorpion extract.
Polarization Technology
A specifically generated monopole electromagnetic vibration creates a resonance effect with Escozine™’s main ingredients at the molecular level; this leads to absorption of energy and shortens the orbital movement of atoms which, in turn, leads to the increase of activity of polarized molecules, and intensifying their potency. Polarization increases the molecular vibration and is excited when the molecule absorbs a quantum of energy, E, corresponding to the vibration’s frequency, ?, according to the relation E = h? (where h is Planck’s constant). A fundamental vibration is excited when one such quantum of energy is absorbed by the molecule in its ground state. This patented technology allows less compounds to be used while increasing the effectiveness of Escozine™’s main ingredients.
Continuation of Patent
Medolife is in the process of applying for a patent continuation, in which these new topics will be covered in detail:
1. Pet product version of patent applies to all different applications of polarized scorpion venom solution for cats and dogs as well as livestock. To find out more, please visit Petlife Pharmaceuticals.
2. The first application of the polarization technology has more general impact on the Blue Scorpion extract, where new multiple frequency generation allows it to target several components in Escozine™ simultaneously. This addition of the patent will be geared towards increasing the potency of specific molecules in the compound to achieve a greater effect on the targeted molecules, amino acids, proteins and peptides. This polarization approach can be applied to any nutraceutical to increase the potency and effectiveness without adding additional ingredients.
3. Escozine GNP-1 is in research and development as an advanced anti-cancer drug. The polarized gold nanoparticles combined with a novel peptide, extracted from the Caribbean Blue Scorpion venom, enhance the bioactive compound and increase the effectiveness of the natural compound up to synthetic drug strength by efficiency. The result is a new category of powerful medications without considerable side effects.
